Crowdonomics
All companies
EYECBETTER logo

EYECBETTER

Operating

Eye C Better Corp

Healthcare · La Quinta, CA · Founded 2021

Transforming eye healthcare with AI-driven smart devices and connected care

Post-money valuation ⓘ
$20.2M
As of Dec 2023 · from Reg CF Offering (2023) · pre-money + amount raised, not a traded price
Total raised
$2,185,758
Crowd $161K · Private $2.0M · 4 rounds since 2021
Latest share price
$1.21
Reg CF · Common Stock · Sep 2023 offering price

Financials

FY2021–FY2023 · from SEC filings · hover any figure for its source
$0
−$22K
2021
$0
−$689K
2022
$120
−$806K
2023
RevenueNet income — beside revenue when positive, below the line when a loss
Metric
FY2021 reviewed
FY2022 reviewed
FY2023 unaudited
Income statement
Revenue
$0
$0
$120
Cost of goods sold
$0
$0
$0
Gross margin
—
—
100%
Net income
-$22,064
-$689,186
-$805,509
Taxes paid
$0
$800
$3,619
Balance sheet
Cash
$429,510
$539,597
$162,199
Accounts receivable
$0
$0
$120
Total assets
$429,510
$539,597
$162,319
Short-term debt
$1,911
$1,185
$3,967
Long-term debt
$0
$0
$0
Total liabilities
$1,911
$1,185
$3,967
Other
Headcount
—
4
4

Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited, as the filing’s own report or certification states it. A dashed pill marked * is inferred instead: the SEC minimum for an offering that size, which the issuer may have exceeded. No pill means we couldn’t tell. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.

Valuation over rounds

Pre-money — the valuation set before each round’s money came in
$20.0M
pre-money
Reg CF · Common · Sep 2023

Blue bars are the pre-money valuation the company stated for a priced round.

Share price over rounds

$1.21$0.605$0.4892
Jan 2022Sep 2023
Round offering price or verified disclosed saleDisclosed sale, unverified or year-only

Disclosed sales come from the issuer's own filings (prior-offering lines, audited-statement notes) and are amount ÷ securities sold. A down round is a firm point more than 25 % below the previous firm point of the same share class on a comparable basis; the comparison ignores unverified and year-only lines.

Fundraising history

Raised $160.9K / $1.2MInvestors 85Post-money $20.2M
Raised $100KInvestors 1
Raised $855KInvestors 19

Team

4 people
Joel SolanoFounder
Founder & Chief Executive Officer

Dr. Solano is a board certified, and fellowship trained anterior segment surgeon and glaucoma specialist. He completed his medical training at the world-renowned Mayo Clinic’s main campus in Rochester, MN and has over 15 years of experience with diagnosing and treating patients with severe eye disease. Dr Solano’s expertise includes medical, laser, and surgical treatments of glaucoma.

Joy GlenFounder
Chief Sales and Marketing Officer

Joy is a target driven healthcare transformer with 20 years of executive leadership experience, optimizing go-to-market strategies and revenue efficiencies for healthcare companies. Joy has repeated success in creating top performing teams that bring innovative healthcare solutions to market. Her experience spans Audiology and Ophthalmology healthcare, with a focus on telehealth and med-tech solutions that increase patient outcomes and improve quality of life.

Alan Goodloe
Chief Digital Information Officer

Alan has over 20 years of IT experience and 15 years in executive level positions. He has a proven track record with building highly scalable solutions and enabling data monetization strategies that have yielded multi-million-dollar benefits for some of the best-known brands in the world including Avery Dennison, Coca-Cola, Costco, Lexmark & UPS.

Matthew Rhodes
CFO Consultant

Matt Rhodes has extensive experience in business and investment management spanning multiple industries over 25 years. He has a knack for simplifying complexities and bringing people together toward common objectives. Matthew is part time and works 5-10 hours per week

Names and titles as disclosed on SEC Form C, StartEngine. Bios and photos come from the platform campaign page and may be out of date.

Reg CF annual-report compliance

Not requiredFewer than 300 holders of record

Filed 1 of 3 annual reports (FY2023–FY2025)

85 investors
holder-count proxy

Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.

SEC filings

  • Form C-ARApr 18, 20240001665160-24-000382
    EDGAR
  • Form C-UDec 29, 20230001665160-23-002057
    EDGAR
  • Form CSep 25, 20230001665160-23-001780
    EDGAR
  • Form D/AMar 31, 20220001884453-22-000002
    EDGAR
  • Form DJan 11, 20220001884453-22-000001
    EDGAR
  • Form DSep 28, 20210001884453-21-000001
    EDGAR
Source: ManualCIK 0001884453CAShare price $1.21

About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.